Diana Brainard Email

CEO . AlloVir

Current Roles

Employees:
130
Revenue:
$22.6M
About
AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The companyᅢᄁ¬ツᆲ¬トᄁs technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVirᅢᄁ¬ツᆲ¬トᄁs technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
AlloVir Address
1100 Winter Street
Cambridge, MA
United States

Past Companies

AlloVirChief Executive Officer
AlloVirIndependent Director, Board of Directors
Gilead SciencesSenior Vice President, Virology Therapeutic Area Head

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.